Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ48MR)

This product GTTS-WQ48MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNFRSF17 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001192.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 608
UniProt ID Q02223
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ48MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13234MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-05082566
GTTS-WQ12410MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NI-0401
GTTS-WQ4937MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ5489MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CDP 6038
GTTS-WQ5785MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ8689MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ10635MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY-3303560
GTTS-WQ1811MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AFD Anti-fD
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW